Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Pulmonology
•
Obstructive Lung Disease
Do you routinely consider evaluation for EDAC in patients with asthma or COPD on maximal inhaler therapy who have refractory symptoms?
Related Questions
What is your approach to inhaler therapy in a patient with asthma who cannot be on an inhaled corticosteroid due to ocular disease?
Do you use hypercapnia as an exclusion criteria in all patients that are being assessed for bronchoscopic lung volume reduction?
What is your approach to the work up and evaluation of loss of asthma control while on a biologic such as dupilumab?
Is there a role for biologics to improve lung function in patients who have severe asthma with daily symptoms and reduced lung function but do not experience frequent exacerbations?
Do you check blood eosinophil counts in patients with COPD exacerbations to help guide therapy decisions?
Is methacholine challenge on its way out?
What is your approach to de-escalation of asthma inhaler therapy in the setting of negative bronchoprovocation testing when patients are averse to deprescribing.
Will you incorporate ensifentrine in the treatment regimen of patients with COPD on baseline dual or triple inhaler therapy?
Do you use bronchodilator response to distinguish between asthma, COPD, or asthma-COPD overlap?
How do you factor smoking history into biologic selection for asthma since the clinical trials generally excluded these patients?
